<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02347839</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO1004</org_study_id>
    <secondary_id>wsy005</secondary_id>
    <nct_id>NCT02347839</nct_id>
  </id_info>
  <brief_title>NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.</brief_title>
  <acronym>NEGOTIATE</acronym>
  <official_title>A Multicenter Phase II Trial of Neoadjuvant Gefitinib Followed by Surgery, Followed by Adjuvant Gefitinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to studying neoadjuvant gefitinib followed by surgery, followed&#xD;
      by adjuvant gefitinib to see how well it works in treating patients with unresectable stage&#xD;
      III NSCLC harboring EGFR mutations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Concurrent chemoradiotherapy is the recommended therapeutic approach for patients with&#xD;
      unresectable stage III non-small cell lung cancer (NSCLC), although surgery offers the chance&#xD;
      of cure. With combined-modality therapy with radiation therapy and chemotherapy, the&#xD;
      prognosis of stage III NSCLC remains poor. Gefitinib has shown great efficacy in NSCLC&#xD;
      patients with EGFR mutations. This study is to studying neoadjuvant gefitinib followed by&#xD;
      surgery, followed by adjuvant gefitinib to see how well it works in treating patients with&#xD;
      unresectable EGFR mutant stage III NSCLC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resectability rate</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with perioperative complications</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>2 years after the last patient is randomized</time_frame>
    <description>Event-free survival was assessed from randomization to disease recurrence/progression or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after the last patient is randomized</time_frame>
    <description>Overall survival was assessed from randomization to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">37</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefitinib-surgery-gefitinib. Induction gefitinib therapy was given for 8 weeks. Patients' resectability was assessed after 8-week gefitinib. Adjuvant gefitinib was given within 3-6 weeks after surgery until progression or unacceptable toxic effects.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gefitinib-surgery-gefitinib</intervention_name>
    <description>neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>neooadjuvant gefitinib followed by surgery and gefitinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Target population is unresectable stage III (III A-bulky N2, III B) NSCLC with EGFR&#xD;
             activating mutation in exon 19 or 21&#xD;
&#xD;
          -  Written informed consent provided&#xD;
&#xD;
          -  Aged 18-75 years&#xD;
&#xD;
          -  Able to comply with the required protocol and follow-up procedures&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Had a life expectancy of 12 weeks or more&#xD;
&#xD;
          -  Adequate hematological function, liver function and renal function&#xD;
&#xD;
          -  Female participants should not be pregnant or breast-feeding&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known severe hypersensitivity to gefitinib or any of the excipients of this product&#xD;
&#xD;
          -  Inability to comply with protocol or study procedures&#xD;
&#xD;
          -  Had had previous chemotherapy, radiotherapy, or agents directed at the HER axis (e.g.&#xD;
             erlotinib, gefitinib, cetuximab, trastuzumab)&#xD;
&#xD;
          -  Had a history another malignancy in the last 5 years with the exception of cured basal&#xD;
             cell carcinoma of the skin, cured in situ carcinoma of the uterine cervix and cured&#xD;
             epithelial carcinoma of the bladder&#xD;
&#xD;
          -  Interstitial pneumonia&#xD;
&#xD;
          -  Eye inflammation not fully controlled or conditions predisposing the subject to this&#xD;
&#xD;
          -  Any unstable systemic disease (including active infection, uncontrolled hypertension,&#xD;
             unstable angina, congestive heart failure, myocardial infarction within the previous&#xD;
             year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic&#xD;
             disease)&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Pregnancy or breast-feeding women&#xD;
&#xD;
          -  History of neurologic or psychiatric disorders&#xD;
&#xD;
          -  Ingredients mixed with small cell lung cancer patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Si-Yu Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Province Association Study of Thoracic Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Si-Yu Wang, MD</last_name>
    <phone>+86 20 87343439</phone>
    <email>wsysums@163.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Si-Yu Wang, Doctor</last_name>
      <phone>+86 20 87343439</phone>
      <email>wsysums@163.net</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>January 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2015</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Si-Yu Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

